NL-OMON46584已完成不适用
Prospective Multi-Center, Single Arm Post-Market Study (PMS) of the Shockwave Medical, Inc. Coronary Lithoplasty® System in Coronary Arteries - Disrupt CAD II
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Subjects are required to meet all of the following inclusion criteria in order to be included in this study.;Inclusion Criteria
- •1. Patient is >= 18 years of age
- •2. Troponin must be less than or equal to the upper limit of lab normal value within 24 hours prior to the procedure OR if troponin is elevated, concomitant CK must be normal
- •3. The target vessel must have a TIMI flow 3 at baseline
- •4. Patients with significant (>= 50% diameter stenosis) native coronary artery disease including stable or unstable angina and silent ischemia, suitable for PCI
- •5. Ability to tolerate dual antiplatelet agent (i.e. aspirin, clopidogrel, prasugrel, or ticagrelor for 1 year and single antiplatelet therapy for life
- •6. Single lesion stenosis of protected LMCA, or LAD, RCA or LCX artery >=50% in a reference vessel of 2.5 mm - 4.0 mm diameter and <= 32 mm length
- •7. Presence of calcification within the lesion on both sides of the vessel as assessed by angiography
- •8. Planned treatment of single lesion in one vessel
- •9. Ability to pass a 0.014* guide wire across the lesion
- •10. Patient, or authorized representative, signs a written Informed Consent form to participate in the study, prior to any study-mandated procedures
- •11. Patient is able and willing to comply with all assessments in the study;Angiographic Inclusion Criteria
- •1. Target lesion is located in a native LMCA, LAD, RCA or LCX artery. A single lesion may be treated per protocol
- •2. Target lesion reference vessel diameter is between 2.5 mm and 4.0 mm (visual estimate)
- •3. Target lesion is <= 32 mm in length
- •4. Stenosis of LMCA, LAD, RCA or LCX artery >=50%
- •5. Calcification within the lesion on both sides of the vessel
- •6. Ability to pass a 0.014* guidewire across the lesion
排除标准
- •Subjects who meet any of the following exclusion criteria will not be included in this study.;Exclusion Criteria
- •1. Concomitant use of Atherectomy, specialty balloon, or investigational coronary devices
- •2. Prior PCI procedure within the last 30 days of the index procedure
- •3. Patient has planned cardiovascular interventions within 30 days post index procedure
- •4. Second lesion with >=50% stenosis in the same target vessel
- •5. Left ventricular ejection fraction < 40%
- •6. Patient refusing or not a candidate for emergency coronary artery bypass grafting (CABG) surgery
- •7. Uncontrolled severe hypertension (systolic BP >180 mm Hg or diastolic BP >110 mm Hg)
- •8. Severe renal failure with serum creatinine >2.5 mg/dL, unless on chronic dialysis
- •9. Untreated pre-procedural hemoglobin <10 g/dL
- •10. Coagulopathy manifested by platelet count <100,000 or International Normalized ratio (INR) >1.7 (INR is only required in patients who have taken warfarin within 2 weeks of enrollment)
- •11. Patients in cardiogenic shock
- •12. Acute myocardial infarction (MI) within the past one (1) month, and/or signs of active myocardial ischemia at the time of enrollment including elevated Troponin-I or T (with concomitant elevation of CK), ischemic ECG changes or chest pain
- •13. History of a stroke or transient ischemic attack (TIA) within 3 months
- •14. NYHA class III or IV heart failure
- •15. Active peptic ulcer or upper gastrointestinal (GI) bleeding within 6 months
- •16. Patients with a life expectancy of less than 1 year
- •17. Target vessel < 2.4 mm in diameter
- •18. Target lesion > 32 mm in length
- •19. Chronic Total Occlusion (CTO)
- •20. Previous stent procedure within 5 mm of target lesion
- •21. Angiographic evidence of a target lesion severe dissection prior to Coronary Lithoplasty treatment
- •22. Unprotected Left Main diameter stenosis >= 50%
- •23. Visible thrombus (by angiography) at target lesion site
- •24. Target lesion is located in a native vessel distal to anastomosis with a saphenous vein graft or LIMA/RIMA bypass
- •25. Patient has active systemic infection
- •26. Patient has connective tissue disease (e.g., Marfan*s syndrome)
- •27. Patient has a hypercoagulable disorder
- •28. Uncontrolled insulin dependent diabetes
- •29. Patient has allergy to imaging contrast media for which they cannot be pre-medicated
- •30. Evidence of aneurysm in target vessel
- •31. Patient is pregnant or nursing;Angiographic Exclusion Criteria
- •Patients that do not meet the final angiographic eligibility criteria will be documented as angiographic screen failures and will not be considered enrolled into the study and no data collection will be completed. Only patients that meet final angiographic eligibility criteria will be enrolled into the study and undergo treatment with the study device and followed per the clinical protocol with data collection.
研究者
相似试验
进行中（未招募）
4 期
The safety and Effectiveness of Botulinum Toxin Type A used for treatment of Moderate to Severe Facial WrinklesCTRI/2020/08/027413Gufic Biosciences Limited100
招募中
不适用
Prospective, multicentre single-arm Post-Market Clinical Follow-up (PMCF) study to evaluate safety and performance of the BeYond Venous Self-Expanding StentI80.1I80.2I87.0Phlebitis and thrombophlebitis of femoral veinPhlebitis and thrombophlebitis of other deep vessels of lower extremitiesPostthrombotic syndromeDRKS00024063Bentley InnoMed GmbH110
尚未招募
不适用
Prospective, Multicenter, Post-market, Single Arm study to confirmthe performance of the RenzanTM Peripheral Stent System in treating Superficial Femoral and/or Popliteal artery diseasenarrowed leg arteriesperipheral disease10003216NL-OMON51143Terumo10
尚未招募
4 期
A clinical trial to assess the efficacy and safety of Formoterol fumarate and Fluticasone propionate powder for inhalation (Formoflo 250) in the patients withAsthmaCTRI/2023/08/056250upin Limited
尚未招募
4 期
Observational Real World National Registry of Dafodil.CTRI/2022/07/044021Meril Life Sciences Pvt Ltd